TERN_101



NAME OF DRUG : TERN_101

ALSO KNOWN AS : TERN_101

LABORATORY : TERNS

STATUS AND ADVANCEMENT

Type of drug : FXR Agonist

Clinical trials advancement : Initiating Phase 2a

Estimated time to market : 123 months.

LABORATORY ABSTRACT ON THE DRUG

FXR is a nuclear receptor expressed in high amounts in the liver and small intestine. Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation and fibrosis. It is believed by many in the scientific community that FXR agonism and activation has potential as a new treatment modality for nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). TERN-101 is a potent non-bile acid FXR agonist being developed as a therapeutic for NASH.

HISTORY AND ANALYSIS

TERNS PHARMACEUTICALS, INC. is a ELI LILLY company

 

RECENT NEWS ON TERN_101

SOME PUBLICATIONS RELATED WITH TERN_101

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH TERN_101


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE